The company is under further criticism on Friday after it was revealed that it spent $4 million to lobby congress to recommend all schools in the U.S. carry the potentially lifesaving EpiPens. The lobbying worked with the 2013 School Access to Emergency Epinephrine Act.
The act provides schools with incentives if they purchase EpiPens.
At least eleven states require public schools to carry EpiPens following the passing of the Act, according to a report from the RawStory. The company’s profits soared 22.5% between 2013 and 2015.
Outrage occurred when the company completed a corporate inversion which moved the company to the Netherlands. The move allowed the company to move its headquarters to a tax haven, resulting in no U.S. taxes being paid.
The company lobbied for the law and receives millions of dollars through federal programs in the United States. Funds are provided through federal programs to cover the increasing costs of EpiPens.
The cost of EpiPens in 2009 was $104. The price was raised to $265 in 2013 and is now $608. The company purchased the rights to the life-saving medicine from Merck.
The CEO of the company, Heather Bresch, is the daughter of Senator Joe Manchin of West Virginia. The CEO’s father did not sponsor the bill. Bresch was given $25.8 million after the successful lobbying. The CEO made $4.9 million in 2009 and raised her salary to $19 million as of last year. Bresch’s compensation has risen over 600%.
EpiPen prices are up over $100 in the last year alone.
The company has a 55% operating margin on EpiPens. The company posted $9.45 billion in revenue with $847.6 million in net profit in 2015.
Post originally appeared on Legal Scoops